CSIMarket Company Name, Ticker, Competitors, else..
 
Neuraxis Inc   (NYSEAMER: NRXS)
 
Price: $6.0100 $0.01 0.167%
Day's High: $6.059999942779541 Week Perf: -0.5 %
Day's Low: $ 5.91 30 Day Perf: -3.84 %
Volume (M): 52,516 52 Wk High: $ 9.33
Volume (M$): $ 0 52 Wk Avg: $5.27
Open: $6.00 52 Wk Low: $2.21



 Market Capitalization (Millions $) 66
 Shares Outstanding (Millions) 11
 Employees 24
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Neuraxis Inc. is a biotechnology company that specializes in the development of advanced neuroscience solutions. The company focuses on the research and development of innovative therapies and diagnostics for various neurological disorders. They aim to improve the understanding of the brain and its disorders, identify new treatment options, and enhance patient outcomes. Neuraxis Inc. collaborates with academic institutions, clinical experts, and industry partners to advance their technologies and bring their products to market.


   Company Address: 11611 N. Meridian Street Carmel 46032 IN
   Company Phone Number: 689-0791   Stock Exchange / Ticker: NYSEAMER NRXS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IKT   -7.6%    
• View Complete Report
   



Management Announcement

NeurAxis Inc.: Bridging Challenges and Triumphs in Neuromodulation Therapy

Published Mon, Jan 13 2025 2:00 PM UTC

In the rapidly evolving healthcare sector, NeurAxis Inc. (NYSE American: NRXS) is a notable player, focusing on the commercialization of neuromodulation therapies aimed at alleviating chronic ailments in both children and adults. A recent letter from CEO Brian Carrico to shareholders provided insights into the company’s trajectory, including achievements in 2024 and a visi...
Management Announcement

NeurAxis Expands Access to Percutaneous Electrical Nerve Field Stimulation with New Coverage Agreements in Pennsylvania and North Dakota

Published Tue, Oct 29 2024 1:01 PM UTC

NeurAxis Expands Access to Percutaneous Electrical Nerve Field Stimulation with New Coverage Agreements in Pennsylvania and North DakotaCARMEL, Ind. — NeurAxis, Inc. (NYSE American: NRXS), a pioneering medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, has made significant strides in expanding access to its innovative t...
Clinical Study

NeurAxis Receives Medical Policy Coverage for Percutaneous Electrical Nerve Field Stimulation in North Dakota

Published Tue, Apr 23 2024 1:01 PM UTC

NeurAxis, Inc. (NeurAxis), a leading medical technology company specializing in neuromodulation therapies for chronic conditions, has recently made a significant breakthrough. The company has announced the successful publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) in North Dakota. This development is expected to have a signi...
Clinical Study

Significant Advancements in Pediatric DGBI Management: Unraveling the Efficacy of NeurAxis’s IB-Stim Neuromodulation Therapy

Published Wed, Mar 27 2024 1:01 PM UTC

Over the past few years, the sphere of neuromodulation for medical therapy has undergone significant advancements, offering a new legion of therapeutic possibilities for diagnosing and treating chronic and debilitating conditions. A prime example is NeurAxis, Inc., a leading medical technology company that has made significant strides in commercializing neuromodulation thera...
Product Service News

NeurAxis Secures Highmark Blue Cross Blue Shield Policy Coverage, Expanding Access to Neurostimulation Therapies

Published Mon, Mar 11 2024 1:01 PM UTC

NeurAxis, a leading medical technology company specializing in neuromodulation therapies for chronic and debilitating conditions, has recently announced a significant breakthrough in expanding patient access to its life-changing treatments. The company revealed that it has successfully obtained policy coverage from Highmark Blue Cross Blue Shield (Highmark BCBS), a prominent...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 15.37
Price to Sales (Expected) -
Price to Book 11.45
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.62
Working Capital Ratio 3.02
Leverage Ratio (MRQ) 0.52
Total Debt to Equity 0.02
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.78 $
Revenues (TTM) 0.39 $
Cash Flow (TTM) 0.46 $
Cash 0.65 $
Book Value 0.52 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 178,396
Net Income per Employee (TTM) -303,471
Receivable Turnover Ratio (TTM) 20.94
Inventory Turnover Ratio (TTM) 3.48
Asset Turnover Ratio (TTM) 0.61

Profitability Ratios Current
Gross Margin (MRQ) 86.42 %
Operating Margin (MRQ) -108.26 %
Net Margin (MRQ) -109.55 %
Net Cash Flow Margin (MRQ) 131.45 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Neuraxis Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.